Johnson & Johnson (NYSE:JNJ) Given Consensus Recommendation of “Moderate Buy” by Brokerages

by · The Markets Daily

Shares of Johnson & Johnson (NYSE:JNJ – Get Free Report) have received an average recommendation of “Moderate Buy” from the twenty-seven brokerages that are presently covering the company, Marketbeat Ratings reports. Nine analysts have rated the stock with a hold rating, fourteen have given a buy rating and four have given a strong buy rating to the company. The average twelve-month price target among brokerages that have issued ratings on the stock in the last year is $211.25.

Several equities analysts have recently issued reports on JNJ shares. Daiwa America raised Johnson & Johnson from a “hold” rating to a “strong-buy” rating in a research report on Monday, October 20th. Weiss Ratings reiterated a “buy (b)” rating on shares of Johnson & Johnson in a report on Friday, October 31st. Guggenheim increased their price objective on shares of Johnson & Johnson from $206.00 to $227.00 and gave the stock a “buy” rating in a research report on Friday, December 5th. Scotiabank began coverage on shares of Johnson & Johnson in a research report on Thursday, November 13th. They issued a “sector outperform” rating and a $230.00 price objective on the stock. Finally, Royal Bank Of Canada set a $240.00 target price on Johnson & Johnson in a report on Wednesday, December 17th.

Get Our Latest Report on JNJ

Johnson & Johnson Stock Up 0.1%

JNJ opened at $207.26 on Friday. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.07 and a quick ratio of 0.80. The firm’s fifty day moving average price is $201.17 and its two-hundred day moving average price is $182.85. Johnson & Johnson has a fifty-two week low of $140.68 and a fifty-two week high of $215.18. The company has a market capitalization of $499.35 billion, a P/E ratio of 20.01, a P/E/G ratio of 2.13 and a beta of 0.34.

Johnson & Johnson (NYSE:JNJ – Get Free Report) last posted its earnings results on Wednesday, August 30th. The company reported $2.26 earnings per share (EPS) for the quarter. The company had revenue of $24.02 billion during the quarter. Johnson & Johnson had a net margin of 27.26% and a return on equity of 32.73%. On average, analysts anticipate that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, March 10th. Shareholders of record on Tuesday, February 24th will be paid a $1.30 dividend. This represents a $5.20 annualized dividend and a yield of 2.5%. The ex-dividend date is Tuesday, February 24th. Johnson & Johnson’s payout ratio is presently 50.19%.

Institutional Trading of Johnson & Johnson

Several institutional investors and hedge funds have recently bought and sold shares of JNJ. Boltwood Capital Management lifted its holdings in shares of Johnson & Johnson by 1.3% during the fourth quarter. Boltwood Capital Management now owns 4,263 shares of the company’s stock worth $882,000 after buying an additional 54 shares in the last quarter. Global Wealth Strategies & Associates raised its stake in Johnson & Johnson by 6.6% in the 4th quarter. Global Wealth Strategies & Associates now owns 1,928 shares of the company’s stock worth $399,000 after purchasing an additional 119 shares in the last quarter. Advisors Management Group Inc. ADV boosted its holdings in Johnson & Johnson by 2.6% in the 3rd quarter. Advisors Management Group Inc. ADV now owns 29,561 shares of the company’s stock valued at $5,481,000 after purchasing an additional 736 shares during the period. AIA Group Ltd increased its holdings in shares of Johnson & Johnson by 70.5% during the third quarter. AIA Group Ltd now owns 112,856 shares of the company’s stock worth $20,926,000 after purchasing an additional 46,682 shares during the period. Finally, Financial Symmetry Inc acquired a new stake in shares of Johnson & Johnson in the third quarter valued at approximately $346,000. Institutional investors own 69.55% of the company’s stock.

Johnson & Johnson Company Profile

(Get Free Report)

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.

Read More